デフォルト表紙
市場調査レポート
商品コード
1758033

胆道がんの世界市場

Biliary Tract Cancers

出版日
ページ情報
英文 282 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=155.10円
胆道がんの世界市場
出版日: 2025年06月27日
発行: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.)
ページ情報: 英文 282 Pages
納期: 即日から翌営業日
GIIご利用のメリット

  • 全表示

  • 概要
  • 目次
概要

胆道がんの世界市場は2030年までに7億7,870万米ドルに達する見込み

2024年に6億2,580万米ドルと推定される胆道がんの世界市場は、2030年には7億7,870万米ドルに達し、分析期間2024～2030年のCAGRは3.7%で成長すると予測されます。本レポートで分析したセグメントの1つである肝内胆管がんは、CAGR 3.5%を記録し、分析期間終了時には4億4,730万米ドルに達すると予測されます。肝外胆管がんセグメントの成長率は、分析期間でCAGR 4.3％と推定されます。

米国市場は1億7,050万米ドルと推定、中国はCAGR6.8％で成長予測

米国の胆道がん市場は、2024年に1億7,050万米ドルと推定されます。世界第2位の経済大国である中国は、分析期間2024-2030年のCAGRを6.8%として、2030年までに1億5,610万米ドルの市場規模に達すると予測されています。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ1.5％と2.9％と予測されています。欧州では、ドイツがCAGR 2.1%で成長すると予測されています。

世界の胆道がん市場- 主要動向と促進要因のまとめ

胆道がんが世界的に医療・研究の注目を集める理由とは？

胆管がん、胆嚢がん、脾臓がんなどの胆道がんは、世界の罹患率の増加、診断の複雑さ、予後の悪さなどから、ますます注目を集めています。これらのがんは胆管、胆嚢、または関連構造物に発生し、進行するまで無症状であることが多く、早期発見が持続的な課題となっています。特に低・中所得国では認知度が低く、スクリーニングのプロトコールもほとんどないため、患者の大半は手術不能または転移の段階で診断されます。原発性硬化性胆管炎、肝フルク感染、慢性胆道炎、ある種の遺伝子変異などの危険因子が、先進国でも新興国でも有病率の上昇に寄与しています。東南アジアやラテンアメリカでは、Opisthorchis viverriniやClonorchis sinensisのような風土病的寄生虫感染が胆管がん発生率の上昇に関連しています。一方、肥満、糖尿病、メタボリックシンドロームの増加は、欧米の人々の胆嚢がんの発生に寄与していると考えられています。胆道がんは歴史的にあまり知られていないにもかかわらず、その攻撃的な性質と新規診断法および標的治療法の重要な必要性から、現在臨床的に注目されています。胆道がんの希少性と不均一性は調査課題にもなっており、疾患メカニズムや治療反応を理解するために世界の協力体制の強化が必要です。がん専門医や医療システムがこの領域における緊急のアンメットニーズを認識するにつれ、胆道がんはがん医療における重要なフロンティアとなりつつあり、より強固なヘルスケア、政策、研究介入が求められています。

診断と画像診断の進歩は、胆道がんの発見をどのように変えているのか？

画像技術、分子診断、バイオマーカー研究における最近の進歩は、課題は残るもの、胆道がんの検出と特徴づけを著しく向上させています。従来、診断は症状や肝酵素の上昇、超音波やCTスキャンなどの画像診断に頼っていたが、早期腫瘍に対する感度が低いことが多くなりました。今日、造影MRI、MRCP（磁気共鳴胆管膵管造影）、PET-CTスキャンなどの高解像度画像診断法により、胆道がより詳細に可視化され、腫瘍の局在診断、病期診断、手術計画がより良好に行えるようになりました。ERCP（内視鏡的逆行性胆管膵管造影）やEUS（内視鏡的超音波）のような内視鏡技術は、組織サンプリング機能を提供し、診断精度を向上させる。リキッドバイオプシー・プラットフォームと次世代シーケンサー（NGS）の開発により、早期発見と変異プロファイリングに新たな扉が開かれ、より正確で個別化された治療戦略が可能になりました。CA19-9やCEAを含む主要なバイオマーカーは、非特異的ではあるが、画像データと組み合わせることで疾患の進行をモニタリングするのに役立っています。さらに、循環腫瘍DNA（ctDNA）、マイクロRNAシグネチャー、メチル化パターンの探索は、非侵襲的な血液ベースの診断ツールへの進歩を促しています。これらのツールは、生検が危険であったり解剖学的に困難であったりする場合に特に価値があります。AIを活用した画像解析や予測アルゴリズムも台頭してきており、微妙な異常を特定し、診断の遅れを軽減する可能性を提供しています。資源が限られた環境では、アクセシビリティとコストが依然として障壁となっているが、こうした診断技術革新は、胆道がんの発見・管理方法を着実に変革し、早期介入と患者の転帰改善に道を開きつつあります。

どのような治療の進歩が胆道がんの治療状況を変えているのか？

胆道がんの治療環境は、全身療法、精密腫瘍学、外科技術の開発により、顕著な変貌を遂げつつあります。歴史的に、治療の選択肢は外科手術と緩和的化学療法に限られており、治癒の可能性があるのは切除術のみでした。しかし、切除可能な患者の割合は30％以下であり、再発率は依然として高いです。ゲムシタビンやシスプラチンのような標準的な化学療法レジメンの有効性は緩やかであり、より個別化された標的アプローチへのシフトを促しています。分子プロファイリングの出現により、FGFR2融合、IDH1変異、HER2過剰発現、MSI高値など、患者のサブセットにおける実用的な変異が同定され、ペミガチニブ、イボシデニブ、トラスツズマブなどの標的療法の開発につながりました。免疫療法、特にペムブロリズマブやニボルマブのようなチェックポイント阻害剤はMSI高値やPD-L1陽性の腫瘍に有望であるが、奏効は様々です。現在進行中の臨床試験では、耐性を克服し奏効率を改善するための併用戦略が検討されています。局所進行例では、放射性塞栓療法、光線力学的療法、経動脈的化学塞栓療法（TACE）などの肝指向性療法がますます使用されるようになっています。腹腔鏡手術やロボット支援手術の進歩により、複雑な切除であっても精度と回復時間が向上しています。さらに、ステント留置、疼痛管理、栄養サポートなどの支持療法は、全人的ケアに不可欠です。世界の臨床試験ネットワークと実世界のデータ登録は、患者集団全体の治療効果の理解を深めています。研究資金と産業界からの投資の増加により、胆道がん治療見通しは徐々に改善されつつあり、これまで限られた選択肢と予後不良に直面してきた患者集団に希望をもたらしています。

胆道がんの世界市場成長の原動力は？

胆道がんの世界市場の成長は、疾病の発生率の上昇、診断法や治療法の進歩、臨床研究の拡大、ヘルスケア支出の増加など、いくつかの集約的な要因によって牽引されています。世界人口の高齢化と、肥満、ウイルス性肝炎、糖尿病、慢性炎症性疾患などの根本的な危険因子の蔓延が、症例発見率の上昇に寄与しています。認知度の向上と医師の教育が診断への警戒心を高め、よりタイムリーな紹介と病期分類の評価につながっています。分子診断や画像診断の技術的進歩は精密医療へのアプローチを促進し、コンパニオン診断やバイオマーカー検査の需要を高めています。さらに、標的治療薬や免疫腫瘍薬が規制当局の承認を取得し、これまで十分な治療を受けていなかった集団で臨床的価値が実証されるなど、医薬品の技術革新が市場の拡大に寄与しています。臨床試験への参加の増加と腫瘍学研究の世界化により、医薬品開発のパイプラインが加速し、より多くの地域で新たな治療法へのアクセスが向上しています。医療システムや保険会社も、希少がんや侵攻性のがんに対処することの経済的・臨床的重要性を認識しており、がんインフラ、登録、集学的治療チームへの投資を促しています。特に有病率の高いアジア太平洋地域では、政府機関や民間団体によるがん研究への資金援助が増加しており、技術革新をさらに促しています。患者擁護活動やオンライン支援ネットワークへのアクセスは、セカンドオピニオン、先進医療、臨床試験登録への需要を高めています。これらすべての促進要因が、治療計画への実世界データの統合の進展と相まって、胆道がん市場の持続的成長を支えており、ニッチな腫瘍学分野から拡大する可能性と戦略的ヘルスケア上の重要性を持つ分野へと変貌を遂げています。

セグメント

がんタイプ（肝内胆管がん、肝外胆管がん、胆嚢がん）、エンドユーザー（病院エンドユーザー、専門がんセンターエンドユーザー、外来手術センターエンドユーザー、その他エンドユーザー）

調査対象企業の例

  • Agios Pharmaceuticals
  • AstraZeneca plc
  • Basilea Pharmaceutica
  • Bayer AG
  • BeiGene Ltd.
  • Bristol Myers Squibb
  • Delcath Systems
  • Eisai Co., Ltd.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd
  • Incyte Corporation
  • Jazz Pharmaceuticals
  • Merck & Co., Inc.（MSD）
  • Novartis AG
  • Pfizer Inc.
  • QED Therapeutics
  • Servier Pharmaceuticals
  • Taiho Pharmaceutical Co., Ltd.
  • TransThera Sciences（Nanjing）
  • Zymeworks Inc.

AI統合

私たちは、有効な専門家コンテンツとAIツールによって、市場情報と競合情報を変革しています。

Global Industry Analystsは、LLMや業界固有のSLMを照会する一般的な規範に従う代わりに、ビデオ記録、ブログ、検索エンジン調査、膨大な量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP36372

Global Biliary Tract Cancers Market to Reach US$778.7 Million by 2030

The global market for Biliary Tract Cancers estimated at US$625.8 Million in the year 2024, is expected to reach US$778.7 Million by 2030, growing at a CAGR of 3.7% over the analysis period 2024-2030. Intrahepatic Cholangiocarcinoma, one of the segments analyzed in the report, is expected to record a 3.5% CAGR and reach US$447.3 Million by the end of the analysis period. Growth in the Extrahepatic Cholangiocarcinoma segment is estimated at 4.3% CAGR over the analysis period.

The U.S. Market is Estimated at US$170.5 Million While China is Forecast to Grow at 6.8% CAGR

The Biliary Tract Cancers market in the U.S. is estimated at US$170.5 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$156.1 Million by the year 2030 trailing a CAGR of 6.8% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.5% and 2.9% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.1% CAGR.

Global Biliary Tract Cancers Market - Key Trends & Drivers Summarized

Why Are Biliary Tract Cancers Drawing Increasing Medical and Research Attention Worldwide?

Biliary tract cancers, which include cholangiocarcinoma, gallbladder cancer, and ampullary cancer, are drawing growing attention due to their increasing global incidence, complex diagnosis, and poor prognosis. These cancers originate in the bile ducts, gallbladder, or associated structures and are often asymptomatic until advanced stages, making early detection a persistent challenge. With limited awareness and few screening protocols in place, especially in low- and middle-income countries, the majority of patients are diagnosed at inoperable or metastatic stages. Risk factors such as primary sclerosing cholangitis, liver fluke infections, chronic biliary inflammation, and certain genetic mutations contribute to rising prevalence in both developed and emerging regions. In Southeast Asia and Latin America, endemic parasitic infections like Opisthorchis viverrini and Clonorchis sinensis are linked to elevated cholangiocarcinoma rates. Meanwhile, increasing obesity, diabetes, and metabolic syndromes are believed to be contributing to gallbladder cancer cases in Western populations. Despite its historically low profile, biliary tract cancer is now receiving more clinical focus due to its aggressive nature and the critical need for novel diagnostics and targeted therapies. The rarity and heterogeneity of these cancers also pose research challenges, necessitating greater global collaboration to understand disease mechanisms and therapeutic responses. As oncologists and health systems recognize the urgent unmet need in this space, biliary tract cancers are becoming a significant frontier in oncology, demanding more robust healthcare, policy, and research interventions.

How Are Diagnostic and Imaging Advances Transforming the Detection of Biliary Tract Cancers?

Recent advances in imaging technologies, molecular diagnostics, and biomarker research are significantly improving the detection and characterization of biliary tract cancers, although challenges remain. Traditionally, diagnosis relied on symptoms, elevated liver enzymes, and imaging techniques like ultrasound or CT scans, which often lacked sensitivity for early-stage tumors. Today, high-resolution imaging modalities such as contrast-enhanced MRI, MRCP (magnetic resonance cholangiopancreatography), and PET-CT scans provide more detailed visualization of the biliary tree, allowing better tumor localization, staging, and surgical planning. Endoscopic techniques like ERCP (endoscopic retrograde cholangiopancreatography) and endoscopic ultrasound (EUS) offer tissue sampling capabilities and enhanced diagnostic precision. The development of liquid biopsy platforms and next-generation sequencing (NGS) has opened new doors for early detection and mutation profiling, enabling more precise and individualized treatment strategies. Key biomarkers, including CA 19-9 and CEA, while nonspecific, continue to aid in monitoring disease progression when combined with imaging data. Moreover, the exploration of circulating tumor DNA (ctDNA), microRNA signatures, and methylation patterns is driving progress toward non-invasive, blood-based diagnostic tools. These tools are particularly valuable in cases where biopsies are risky or anatomically difficult. AI-enhanced imaging analytics and predictive algorithms are also emerging, offering potential in identifying subtle anomalies and reducing diagnostic delays. Although accessibility and cost remain barriers in resource-limited settings, these diagnostic innovations are steadily transforming how biliary tract cancers are detected and managed, paving the way for earlier interventions and improved patient outcomes.

What Therapeutic Advancements Are Reshaping the Treatment Landscape for Biliary Tract Cancers?

The treatment landscape for biliary tract cancers is undergoing notable transformation, driven by developments in systemic therapies, precision oncology, and surgical techniques. Historically, treatment options were limited to surgery and palliative chemotherapy, with resection offering the only potential for cure. However, fewer than 30% of patients present with resectable disease, and recurrence rates remain high. Standard chemotherapy regimens like gemcitabine and cisplatin have modest efficacy, prompting a shift toward more personalized and targeted approaches. The advent of molecular profiling has identified actionable mutations in subsets of patients, such as FGFR2 fusions, IDH1 mutations, HER2 overexpression, and MSI-high status, leading to the development of targeted therapies like pemigatinib, ivosidenib, and trastuzumab. Immunotherapy, particularly checkpoint inhibitors like pembrolizumab and nivolumab, has shown promise in MSI-high and PD-L1-positive tumors, though responses vary. Ongoing trials are investigating combination strategies to overcome resistance and improve response rates. Liver-directed therapies, including radioembolization, photodynamic therapy, and transarterial chemoembolization (TACE), are increasingly used in locally advanced cases. Advances in laparoscopic and robotic-assisted surgery have improved precision and recovery times, even in complex resections. Additionally, supportive care measures such as stenting, pain management, and nutritional support are integral to holistic care. Global clinical trial networks and real-world data registries are enhancing understanding of treatment effectiveness across patient populations. With increased research funding and industry investment, the therapeutic outlook for biliary tract cancers is gradually improving, offering hope to a patient population that has historically faced limited options and poor prognoses.

What Is Fueling the Growth in the Global Biliary Tract Cancers Market?

The growth in the global biliary tract cancers market is driven by several converging factors including rising disease incidence, advancements in diagnostics and therapies, expanding clinical research, and increasing healthcare expenditure. The aging global population and escalating prevalence of underlying risk factors-such as obesity, viral hepatitis, diabetes, and chronic inflammatory conditions-are contributing to higher case detection rates. Enhanced awareness and physician education are improving diagnostic vigilance, leading to more timely referrals and staging assessments. Technological advancements in molecular diagnostics and imaging are facilitating precision medicine approaches, thus increasing demand for companion diagnostics and biomarker testing. Moreover, pharmaceutical innovation is contributing to the market’s expansion, with targeted therapies and immuno-oncology agents gaining regulatory approvals and demonstrating clinical value in previously underserved populations. Increased participation in clinical trials and the globalization of oncology research are accelerating drug development pipelines and improving access to emerging therapies in more regions. Health systems and insurers are also recognizing the economic and clinical importance of addressing rare and aggressive cancers, prompting investments in cancer infrastructure, registries, and multidisciplinary care teams. Rising funding from government bodies and private organizations for cancer research-especially in Asia-Pacific, where disease prevalence is high-is further stimulating innovation. Patient advocacy and access to online support networks are increasing demand for second opinions, advanced care, and clinical trial enrollment. All these drivers, combined with the growing integration of real-world data into treatment planning, are supporting sustained growth in the biliary tract cancers market, transforming it from a niche oncology segment into a field of expanding potential and strategic healthcare significance.

SCOPE OF STUDY:

The report analyzes the Biliary Tract Cancers market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Cancer Type (Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma, Gallbladder Cancer); End-Use (Hospitals End-Use, Specialty Cancer Centers End-Use, Ambulatory Surgery Centers End-Use, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 42 Featured) -

  • Agios Pharmaceuticals
  • AstraZeneca plc
  • Basilea Pharmaceutica
  • Bayer AG
  • BeiGene Ltd.
  • Bristol Myers Squibb
  • Delcath Systems
  • Eisai Co., Ltd.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd
  • Incyte Corporation
  • Jazz Pharmaceuticals
  • Merck & Co., Inc. (MSD)
  • Novartis AG
  • Pfizer Inc.
  • QED Therapeutics
  • Servier Pharmaceuticals
  • Taiho Pharmaceutical Co., Ltd.
  • TransThera Sciences (Nanjing)
  • Zymeworks Inc.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Biliary Tract Cancers - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Incidence and Late Diagnosis of Biliary Tract Cancers Throws the Spotlight on Unmet Clinical Needs
    • Increased Focus on Rare Oncology Segments Spurs Growth in Research and Targeted Therapy Development
    • Molecular Profiling and Biomarker Advancements Drive Adoption of Personalized Treatment Approaches
    • Here's How Immunotherapy Trials Are Reshaping the Treatment Landscape for Biliary Tract Cancers
    • Growing Pipeline of FGFR, IDH1, and HER2 Inhibitors Expands the Addressable Therapeutic Market
    • Limited Efficacy of Standard Chemotherapy Strengthens the Business Case for Novel Drug Combinations
    • Expanded Use of Genomic Testing Supports Patient Selection and Optimizes Treatment Outcomes
    • Clinical Trial Collaborations and Global Consortia Fuel Innovation and Accelerate Regulatory Timelines
    • Regulatory Incentives and Orphan Drug Designation Enhance Market Entry for Niche Therapeutics
    • Rising Healthcare Infrastructure in Emerging Markets Creates New Opportunities for Diagnostic and Treatment Access
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Biliary Tract Cancers Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Biliary Tract Cancers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Biliary Tract Cancers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 4: World 16-Year Perspective for Biliary Tract Cancers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Intrahepatic Cholangiocarcinoma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Intrahepatic Cholangiocarcinoma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 7: World 16-Year Perspective for Intrahepatic Cholangiocarcinoma by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Extrahepatic Cholangiocarcinoma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Extrahepatic Cholangiocarcinoma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 10: World 16-Year Perspective for Extrahepatic Cholangiocarcinoma by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Gallbladder Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Gallbladder Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 13: World 16-Year Perspective for Gallbladder Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Hospitals End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Hospitals End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 16: World 16-Year Perspective for Hospitals End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Specialty Cancer Centers End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Specialty Cancer Centers End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 19: World 16-Year Perspective for Specialty Cancer Centers End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Ambulatory Surgery Centers End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Ambulatory Surgery Centers End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 22: World 16-Year Perspective for Ambulatory Surgery Centers End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 25: World 16-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Biliary Tract Cancers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 26: USA Recent Past, Current & Future Analysis for Biliary Tract Cancers by Cancer Type - Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma and Gallbladder Cancer - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 27: USA Historic Review for Biliary Tract Cancers by Cancer Type - Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma and Gallbladder Cancer Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 28: USA 16-Year Perspective for Biliary Tract Cancers by Cancer Type - Percentage Breakdown of Value Sales for Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma and Gallbladder Cancer for the Years 2014, 2025 & 2030
    • TABLE 29: USA Recent Past, Current & Future Analysis for Biliary Tract Cancers by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 30: USA Historic Review for Biliary Tract Cancers by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 31: USA 16-Year Perspective for Biliary Tract Cancers by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Cancer Centers End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • CANADA
    • TABLE 32: Canada Recent Past, Current & Future Analysis for Biliary Tract Cancers by Cancer Type - Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma and Gallbladder Cancer - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Canada Historic Review for Biliary Tract Cancers by Cancer Type - Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma and Gallbladder Cancer Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 34: Canada 16-Year Perspective for Biliary Tract Cancers by Cancer Type - Percentage Breakdown of Value Sales for Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma and Gallbladder Cancer for the Years 2014, 2025 & 2030
    • TABLE 35: Canada Recent Past, Current & Future Analysis for Biliary Tract Cancers by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Canada Historic Review for Biliary Tract Cancers by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 37: Canada 16-Year Perspective for Biliary Tract Cancers by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Cancer Centers End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • JAPAN
    • Biliary Tract Cancers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 38: Japan Recent Past, Current & Future Analysis for Biliary Tract Cancers by Cancer Type - Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma and Gallbladder Cancer - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Japan Historic Review for Biliary Tract Cancers by Cancer Type - Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma and Gallbladder Cancer Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 40: Japan 16-Year Perspective for Biliary Tract Cancers by Cancer Type - Percentage Breakdown of Value Sales for Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma and Gallbladder Cancer for the Years 2014, 2025 & 2030
    • TABLE 41: Japan Recent Past, Current & Future Analysis for Biliary Tract Cancers by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Japan Historic Review for Biliary Tract Cancers by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 43: Japan 16-Year Perspective for Biliary Tract Cancers by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Cancer Centers End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • CHINA
    • Biliary Tract Cancers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 44: China Recent Past, Current & Future Analysis for Biliary Tract Cancers by Cancer Type - Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma and Gallbladder Cancer - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 45: China Historic Review for Biliary Tract Cancers by Cancer Type - Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma and Gallbladder Cancer Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 46: China 16-Year Perspective for Biliary Tract Cancers by Cancer Type - Percentage Breakdown of Value Sales for Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma and Gallbladder Cancer for the Years 2014, 2025 & 2030
    • TABLE 47: China Recent Past, Current & Future Analysis for Biliary Tract Cancers by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 48: China Historic Review for Biliary Tract Cancers by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 49: China 16-Year Perspective for Biliary Tract Cancers by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Cancer Centers End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • EUROPE
    • Biliary Tract Cancers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 50: Europe Recent Past, Current & Future Analysis for Biliary Tract Cancers by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 51: Europe Historic Review for Biliary Tract Cancers by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 52: Europe 16-Year Perspective for Biliary Tract Cancers by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
    • TABLE 53: Europe Recent Past, Current & Future Analysis for Biliary Tract Cancers by Cancer Type - Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma and Gallbladder Cancer - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Europe Historic Review for Biliary Tract Cancers by Cancer Type - Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma and Gallbladder Cancer Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 55: Europe 16-Year Perspective for Biliary Tract Cancers by Cancer Type - Percentage Breakdown of Value Sales for Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma and Gallbladder Cancer for the Years 2014, 2025 & 2030
    • TABLE 56: Europe Recent Past, Current & Future Analysis for Biliary Tract Cancers by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Europe Historic Review for Biliary Tract Cancers by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 58: Europe 16-Year Perspective for Biliary Tract Cancers by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Cancer Centers End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • FRANCE
    • Biliary Tract Cancers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 59: France Recent Past, Current & Future Analysis for Biliary Tract Cancers by Cancer Type - Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma and Gallbladder Cancer - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 60: France Historic Review for Biliary Tract Cancers by Cancer Type - Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma and Gallbladder Cancer Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 61: France 16-Year Perspective for Biliary Tract Cancers by Cancer Type - Percentage Breakdown of Value Sales for Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma and Gallbladder Cancer for the Years 2014, 2025 & 2030
    • TABLE 62: France Recent Past, Current & Future Analysis for Biliary Tract Cancers by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 63: France Historic Review for Biliary Tract Cancers by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 64: France 16-Year Perspective for Biliary Tract Cancers by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Cancer Centers End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • GERMANY
    • Biliary Tract Cancers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 65: Germany Recent Past, Current & Future Analysis for Biliary Tract Cancers by Cancer Type - Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma and Gallbladder Cancer - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Germany Historic Review for Biliary Tract Cancers by Cancer Type - Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma and Gallbladder Cancer Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 67: Germany 16-Year Perspective for Biliary Tract Cancers by Cancer Type - Percentage Breakdown of Value Sales for Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma and Gallbladder Cancer for the Years 2014, 2025 & 2030
    • TABLE 68: Germany Recent Past, Current & Future Analysis for Biliary Tract Cancers by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Germany Historic Review for Biliary Tract Cancers by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 70: Germany 16-Year Perspective for Biliary Tract Cancers by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Cancer Centers End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • ITALY
    • TABLE 71: Italy Recent Past, Current & Future Analysis for Biliary Tract Cancers by Cancer Type - Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma and Gallbladder Cancer - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Italy Historic Review for Biliary Tract Cancers by Cancer Type - Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma and Gallbladder Cancer Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 73: Italy 16-Year Perspective for Biliary Tract Cancers by Cancer Type - Percentage Breakdown of Value Sales for Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma and Gallbladder Cancer for the Years 2014, 2025 & 2030
    • TABLE 74: Italy Recent Past, Current & Future Analysis for Biliary Tract Cancers by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Italy Historic Review for Biliary Tract Cancers by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 76: Italy 16-Year Perspective for Biliary Tract Cancers by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Cancer Centers End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • UNITED KINGDOM
    • Biliary Tract Cancers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 77: UK Recent Past, Current & Future Analysis for Biliary Tract Cancers by Cancer Type - Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma and Gallbladder Cancer - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 78: UK Historic Review for Biliary Tract Cancers by Cancer Type - Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma and Gallbladder Cancer Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 79: UK 16-Year Perspective for Biliary Tract Cancers by Cancer Type - Percentage Breakdown of Value Sales for Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma and Gallbladder Cancer for the Years 2014, 2025 & 2030
    • TABLE 80: UK Recent Past, Current & Future Analysis for Biliary Tract Cancers by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 81: UK Historic Review for Biliary Tract Cancers by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 82: UK 16-Year Perspective for Biliary Tract Cancers by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Cancer Centers End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • SPAIN
    • TABLE 83: Spain Recent Past, Current & Future Analysis for Biliary Tract Cancers by Cancer Type - Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma and Gallbladder Cancer - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Spain Historic Review for Biliary Tract Cancers by Cancer Type - Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma and Gallbladder Cancer Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 85: Spain 16-Year Perspective for Biliary Tract Cancers by Cancer Type - Percentage Breakdown of Value Sales for Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma and Gallbladder Cancer for the Years 2014, 2025 & 2030
    • TABLE 86: Spain Recent Past, Current & Future Analysis for Biliary Tract Cancers by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Spain Historic Review for Biliary Tract Cancers by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 88: Spain 16-Year Perspective for Biliary Tract Cancers by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Cancer Centers End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • RUSSIA
    • TABLE 89: Russia Recent Past, Current & Future Analysis for Biliary Tract Cancers by Cancer Type - Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma and Gallbladder Cancer - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Russia Historic Review for Biliary Tract Cancers by Cancer Type - Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma and Gallbladder Cancer Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 91: Russia 16-Year Perspective for Biliary Tract Cancers by Cancer Type - Percentage Breakdown of Value Sales for Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma and Gallbladder Cancer for the Years 2014, 2025 & 2030
    • TABLE 92: Russia Recent Past, Current & Future Analysis for Biliary Tract Cancers by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Russia Historic Review for Biliary Tract Cancers by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 94: Russia 16-Year Perspective for Biliary Tract Cancers by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Cancer Centers End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • REST OF EUROPE
    • TABLE 95: Rest of Europe Recent Past, Current & Future Analysis for Biliary Tract Cancers by Cancer Type - Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma and Gallbladder Cancer - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Rest of Europe Historic Review for Biliary Tract Cancers by Cancer Type - Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma and Gallbladder Cancer Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 97: Rest of Europe 16-Year Perspective for Biliary Tract Cancers by Cancer Type - Percentage Breakdown of Value Sales for Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma and Gallbladder Cancer for the Years 2014, 2025 & 2030
    • TABLE 98: Rest of Europe Recent Past, Current & Future Analysis for Biliary Tract Cancers by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Rest of Europe Historic Review for Biliary Tract Cancers by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 100: Rest of Europe 16-Year Perspective for Biliary Tract Cancers by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Cancer Centers End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • ASIA-PACIFIC
    • Biliary Tract Cancers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 101: Asia-Pacific Recent Past, Current & Future Analysis for Biliary Tract Cancers by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 102: Asia-Pacific Historic Review for Biliary Tract Cancers by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 103: Asia-Pacific 16-Year Perspective for Biliary Tract Cancers by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
    • TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Biliary Tract Cancers by Cancer Type - Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma and Gallbladder Cancer - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Asia-Pacific Historic Review for Biliary Tract Cancers by Cancer Type - Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma and Gallbladder Cancer Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 106: Asia-Pacific 16-Year Perspective for Biliary Tract Cancers by Cancer Type - Percentage Breakdown of Value Sales for Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma and Gallbladder Cancer for the Years 2014, 2025 & 2030
    • TABLE 107: Asia-Pacific Recent Past, Current & Future Analysis for Biliary Tract Cancers by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Asia-Pacific Historic Review for Biliary Tract Cancers by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 109: Asia-Pacific 16-Year Perspective for Biliary Tract Cancers by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Cancer Centers End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • AUSTRALIA
    • Biliary Tract Cancers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 110: Australia Recent Past, Current & Future Analysis for Biliary Tract Cancers by Cancer Type - Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma and Gallbladder Cancer - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Australia Historic Review for Biliary Tract Cancers by Cancer Type - Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma and Gallbladder Cancer Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 112: Australia 16-Year Perspective for Biliary Tract Cancers by Cancer Type - Percentage Breakdown of Value Sales for Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma and Gallbladder Cancer for the Years 2014, 2025 & 2030
    • TABLE 113: Australia Recent Past, Current & Future Analysis for Biliary Tract Cancers by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Australia Historic Review for Biliary Tract Cancers by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 115: Australia 16-Year Perspective for Biliary Tract Cancers by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Cancer Centers End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • INDIA
    • Biliary Tract Cancers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 116: India Recent Past, Current & Future Analysis for Biliary Tract Cancers by Cancer Type - Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma and Gallbladder Cancer - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 117: India Historic Review for Biliary Tract Cancers by Cancer Type - Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma and Gallbladder Cancer Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 118: India 16-Year Perspective for Biliary Tract Cancers by Cancer Type - Percentage Breakdown of Value Sales for Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma and Gallbladder Cancer for the Years 2014, 2025 & 2030
    • TABLE 119: India Recent Past, Current & Future Analysis for Biliary Tract Cancers by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 120: India Historic Review for Biliary Tract Cancers by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 121: India 16-Year Perspective for Biliary Tract Cancers by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Cancer Centers End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • SOUTH KOREA
    • TABLE 122: South Korea Recent Past, Current & Future Analysis for Biliary Tract Cancers by Cancer Type - Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma and Gallbladder Cancer - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 123: South Korea Historic Review for Biliary Tract Cancers by Cancer Type - Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma and Gallbladder Cancer Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 124: South Korea 16-Year Perspective for Biliary Tract Cancers by Cancer Type - Percentage Breakdown of Value Sales for Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma and Gallbladder Cancer for the Years 2014, 2025 & 2030
    • TABLE 125: South Korea Recent Past, Current & Future Analysis for Biliary Tract Cancers by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 126: South Korea Historic Review for Biliary Tract Cancers by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 127: South Korea 16-Year Perspective for Biliary Tract Cancers by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Cancer Centers End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 128: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Biliary Tract Cancers by Cancer Type - Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma and Gallbladder Cancer - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Rest of Asia-Pacific Historic Review for Biliary Tract Cancers by Cancer Type - Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma and Gallbladder Cancer Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 130: Rest of Asia-Pacific 16-Year Perspective for Biliary Tract Cancers by Cancer Type - Percentage Breakdown of Value Sales for Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma and Gallbladder Cancer for the Years 2014, 2025 & 2030
    • TABLE 131: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Biliary Tract Cancers by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Rest of Asia-Pacific Historic Review for Biliary Tract Cancers by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 133: Rest of Asia-Pacific 16-Year Perspective for Biliary Tract Cancers by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Cancer Centers End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • LATIN AMERICA
    • Biliary Tract Cancers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 134: Latin America Recent Past, Current & Future Analysis for Biliary Tract Cancers by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 135: Latin America Historic Review for Biliary Tract Cancers by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 136: Latin America 16-Year Perspective for Biliary Tract Cancers by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
    • TABLE 137: Latin America Recent Past, Current & Future Analysis for Biliary Tract Cancers by Cancer Type - Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma and Gallbladder Cancer - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Latin America Historic Review for Biliary Tract Cancers by Cancer Type - Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma and Gallbladder Cancer Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 139: Latin America 16-Year Perspective for Biliary Tract Cancers by Cancer Type - Percentage Breakdown of Value Sales for Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma and Gallbladder Cancer for the Years 2014, 2025 & 2030
    • TABLE 140: Latin America Recent Past, Current & Future Analysis for Biliary Tract Cancers by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Latin America Historic Review for Biliary Tract Cancers by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 142: Latin America 16-Year Perspective for Biliary Tract Cancers by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Cancer Centers End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • ARGENTINA
    • TABLE 143: Argentina Recent Past, Current & Future Analysis for Biliary Tract Cancers by Cancer Type - Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma and Gallbladder Cancer - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Argentina Historic Review for Biliary Tract Cancers by Cancer Type - Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma and Gallbladder Cancer Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 145: Argentina 16-Year Perspective for Biliary Tract Cancers by Cancer Type - Percentage Breakdown of Value Sales for Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma and Gallbladder Cancer for the Years 2014, 2025 & 2030
    • TABLE 146: Argentina Recent Past, Current & Future Analysis for Biliary Tract Cancers by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Argentina Historic Review for Biliary Tract Cancers by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 148: Argentina 16-Year Perspective for Biliary Tract Cancers by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Cancer Centers End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • BRAZIL
    • TABLE 149: Brazil Recent Past, Current & Future Analysis for Biliary Tract Cancers by Cancer Type - Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma and Gallbladder Cancer - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Brazil Historic Review for Biliary Tract Cancers by Cancer Type - Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma and Gallbladder Cancer Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 151: Brazil 16-Year Perspective for Biliary Tract Cancers by Cancer Type - Percentage Breakdown of Value Sales for Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma and Gallbladder Cancer for the Years 2014, 2025 & 2030
    • TABLE 152: Brazil Recent Past, Current & Future Analysis for Biliary Tract Cancers by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Brazil Historic Review for Biliary Tract Cancers by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 154: Brazil 16-Year Perspective for Biliary Tract Cancers by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Cancer Centers End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • MEXICO
    • TABLE 155: Mexico Recent Past, Current & Future Analysis for Biliary Tract Cancers by Cancer Type - Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma and Gallbladder Cancer - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Mexico Historic Review for Biliary Tract Cancers by Cancer Type - Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma and Gallbladder Cancer Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 157: Mexico 16-Year Perspective for Biliary Tract Cancers by Cancer Type - Percentage Breakdown of Value Sales for Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma and Gallbladder Cancer for the Years 2014, 2025 & 2030
    • TABLE 158: Mexico Recent Past, Current & Future Analysis for Biliary Tract Cancers by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Mexico Historic Review for Biliary Tract Cancers by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 160: Mexico 16-Year Perspective for Biliary Tract Cancers by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Cancer Centers End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 161: Rest of Latin America Recent Past, Current & Future Analysis for Biliary Tract Cancers by Cancer Type - Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma and Gallbladder Cancer - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Rest of Latin America Historic Review for Biliary Tract Cancers by Cancer Type - Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma and Gallbladder Cancer Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 163: Rest of Latin America 16-Year Perspective for Biliary Tract Cancers by Cancer Type - Percentage Breakdown of Value Sales for Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma and Gallbladder Cancer for the Years 2014, 2025 & 2030
    • TABLE 164: Rest of Latin America Recent Past, Current & Future Analysis for Biliary Tract Cancers by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Rest of Latin America Historic Review for Biliary Tract Cancers by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 166: Rest of Latin America 16-Year Perspective for Biliary Tract Cancers by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Cancer Centers End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • MIDDLE EAST
    • Biliary Tract Cancers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 167: Middle East Recent Past, Current & Future Analysis for Biliary Tract Cancers by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 168: Middle East Historic Review for Biliary Tract Cancers by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 169: Middle East 16-Year Perspective for Biliary Tract Cancers by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
    • TABLE 170: Middle East Recent Past, Current & Future Analysis for Biliary Tract Cancers by Cancer Type - Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma and Gallbladder Cancer - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Middle East Historic Review for Biliary Tract Cancers by Cancer Type - Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma and Gallbladder Cancer Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 172: Middle East 16-Year Perspective for Biliary Tract Cancers by Cancer Type - Percentage Breakdown of Value Sales for Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma and Gallbladder Cancer for the Years 2014, 2025 & 2030
    • TABLE 173: Middle East Recent Past, Current & Future Analysis for Biliary Tract Cancers by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Middle East Historic Review for Biliary Tract Cancers by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 175: Middle East 16-Year Perspective for Biliary Tract Cancers by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Cancer Centers End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • IRAN
    • TABLE 176: Iran Recent Past, Current & Future Analysis for Biliary Tract Cancers by Cancer Type - Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma and Gallbladder Cancer - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Iran Historic Review for Biliary Tract Cancers by Cancer Type - Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma and Gallbladder Cancer Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 178: Iran 16-Year Perspective for Biliary Tract Cancers by Cancer Type - Percentage Breakdown of Value Sales for Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma and Gallbladder Cancer for the Years 2014, 2025 & 2030
    • TABLE 179: Iran Recent Past, Current & Future Analysis for Biliary Tract Cancers by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Iran Historic Review for Biliary Tract Cancers by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 181: Iran 16-Year Perspective for Biliary Tract Cancers by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Cancer Centers End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • ISRAEL
    • TABLE 182: Israel Recent Past, Current & Future Analysis for Biliary Tract Cancers by Cancer Type - Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma and Gallbladder Cancer - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Israel Historic Review for Biliary Tract Cancers by Cancer Type - Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma and Gallbladder Cancer Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 184: Israel 16-Year Perspective for Biliary Tract Cancers by Cancer Type - Percentage Breakdown of Value Sales for Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma and Gallbladder Cancer for the Years 2014, 2025 & 2030
    • TABLE 185: Israel Recent Past, Current & Future Analysis for Biliary Tract Cancers by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Israel Historic Review for Biliary Tract Cancers by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 187: Israel 16-Year Perspective for Biliary Tract Cancers by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Cancer Centers End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 188: Saudi Arabia Recent Past, Current & Future Analysis for Biliary Tract Cancers by Cancer Type - Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma and Gallbladder Cancer - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Saudi Arabia Historic Review for Biliary Tract Cancers by Cancer Type - Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma and Gallbladder Cancer Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 190: Saudi Arabia 16-Year Perspective for Biliary Tract Cancers by Cancer Type - Percentage Breakdown of Value Sales for Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma and Gallbladder Cancer for the Years 2014, 2025 & 2030
    • TABLE 191: Saudi Arabia Recent Past, Current & Future Analysis for Biliary Tract Cancers by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Saudi Arabia Historic Review for Biliary Tract Cancers by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 193: Saudi Arabia 16-Year Perspective for Biliary Tract Cancers by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Cancer Centers End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 194: UAE Recent Past, Current & Future Analysis for Biliary Tract Cancers by Cancer Type - Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma and Gallbladder Cancer - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 195: UAE Historic Review for Biliary Tract Cancers by Cancer Type - Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma and Gallbladder Cancer Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 196: UAE 16-Year Perspective for Biliary Tract Cancers by Cancer Type - Percentage Breakdown of Value Sales for Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma and Gallbladder Cancer for the Years 2014, 2025 & 2030
    • TABLE 197: UAE Recent Past, Current & Future Analysis for Biliary Tract Cancers by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 198: UAE Historic Review for Biliary Tract Cancers by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 199: UAE 16-Year Perspective for Biliary Tract Cancers by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Cancer Centers End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 200: Rest of Middle East Recent Past, Current & Future Analysis for Biliary Tract Cancers by Cancer Type - Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma and Gallbladder Cancer - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Rest of Middle East Historic Review for Biliary Tract Cancers by Cancer Type - Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma and Gallbladder Cancer Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 202: Rest of Middle East 16-Year Perspective for Biliary Tract Cancers by Cancer Type - Percentage Breakdown of Value Sales for Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma and Gallbladder Cancer for the Years 2014, 2025 & 2030
    • TABLE 203: Rest of Middle East Recent Past, Current & Future Analysis for Biliary Tract Cancers by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Rest of Middle East Historic Review for Biliary Tract Cancers by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 205: Rest of Middle East 16-Year Perspective for Biliary Tract Cancers by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Cancer Centers End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • AFRICA
    • Biliary Tract Cancers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 206: Africa Recent Past, Current & Future Analysis for Biliary Tract Cancers by Cancer Type - Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma and Gallbladder Cancer - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Africa Historic Review for Biliary Tract Cancers by Cancer Type - Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma and Gallbladder Cancer Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 208: Africa 16-Year Perspective for Biliary Tract Cancers by Cancer Type - Percentage Breakdown of Value Sales for Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma and Gallbladder Cancer for the Years 2014, 2025 & 2030
    • TABLE 209: Africa Recent Past, Current & Future Analysis for Biliary Tract Cancers by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Africa Historic Review for Biliary Tract Cancers by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 211: Africa 16-Year Perspective for Biliary Tract Cancers by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Cancer Centers End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030

IV. COMPETITION